Cancer Genetics (CGIX) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Cancer Genetics, Inc. Announces Strong Fourth Quarter and Full-Year 2015 Results and Provides 2016 Business Update
March 10, 2016 3:53 PM ESTFull-Year 2015 revenues up 77% year-over-year to $18 MillionFourth Quarter revenues up 36% year-over-year to $5.5 MillionClosed 2015 with strong cash balance of $19.5 MillionConference call begins at 5:00 p.m. Eastern time today
RUTHERFORD, N.J., March 10, 2016 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq: CGIX), an emerging leader in enabling precision medicine for oncology diagnostics, announced financial and operating results for the fourth quarter and full-year-ended December 31, 2015 and provided an update on the business progress for 2016.
Our business continues to scale as we integrate the acquisition of Response Genetics, focus on expanding our biopharma... More
